Stockreport

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights [Yahoo! Finance]

Inozyme Pharma, Inc.  (INZY) 
PDF – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2 [Read more]